

CONTENTS

I	INTRODUCTION	1
1	INSULIN SIGNALLING	2
1.1	The PI3K-AKT-mTOR Pathway	3
1.2	The GRB2-SOS-RAS-MAPK Pathway	4
1.3	Negative regulators of insulin signalling	4
1.4	Mechanisms of insulin resistance	6
	Lipotoxicity	6
	Hyperglycemia	6
	Unfolded protein response	7
	Inflammation	7
	Mitochondrial Dysfunction and ROS Formation	7
1.5	Glucose import	7
1.5.1	Glut4 translocation	7
	GLUT4 vesicle Tethering	8
1.5.2	GSV Fusion with the plasma membrane	8
2	F-BOX PROTEINS	10
2.1	Substrate recruitment	10
2.2	Regulation of E3 Ligases	12
2.2.1	Activation of E3s by Phosphorylation	12
2.2.2	Regulation of E3 by Ubiquitin-like Modifications	13
2.2.3	Regulation by self-ubiquitination	14
2.2.4	Role of E3 Ligases in development of insulin resistance	14
	Direct insulin signalling targets	14
	Indirect regulation of the insulin signalling	15
2.2.5	F-box only protein 30	15
3	MASS SPECTROMETRY FOR PROTEOMICS	17
3.1	General Introduction	17
3.2	QExactive Series	17
3.2.1	Quadrupole mass filter	17
3.3	The Orbitrap Mass Analyser	22
	Improving Orbitrap performance	24
3.4	Quantification Strategies	25
4	BIOINFORMATICS TOOLS	27
4.1	MaxQuant	27
4.2	Label Free Quantification - MaxLFQ	28
5	AIM OF THIS THESIS	29
II	MATERIAL & METHODS	30
6	MATERIALS	31
6.1	Chemicals	31
6.2	Solutions and Buffers	32
6.3	Enzymes & Proteins	32
6.4	Antibodies	32
6.4.1	Custom anti-Fbxo30	32
6.5	siRNA	33
6.6	Primers	35
6.7	Animals	35

6.8	Published Datasets	37
6.9	Software	38
6.10	Instruments and Hardware	38
7	METHODS	39
7.1	Tissue Lysis	39
7.2	Cell Lysis	39
7.3	Protein Digestion	39
7.3.1	In-Solution	39
7.3.2	In-Gel Digestion	40
7.4	Phosphopeptide Enrichment	40
7.5	Enrichment for GlyGly remnants	42
7.6	Peptide desalting	43
7.7	High-performance Liquid Chromatography and Mass Spectrometry	43
7.8	MaxQuant Data Analysis	44
7.9	In-vitro kinase assay	44
7.10	Western Blotting	45
7.11	In-vitro ubiquitylation assay	45
7.12	PCR	46
7.13	Generation of Fbxo30 ^{-/-} BAT cells by CRISPR	46
7.14	Animal Studies	46
7.14.1	Ethic Aspects	46
7.14.2	Generation of Fbxo30 Knock-out Mice	46
7.14.3	Construct Design	47
7.14.4	Genotyping	47
7.14.5	Insulin tolerance test	48
7.14.6	Glucose tolerance test	49
7.14.7	Micro computed tomography	49
7.15	Software design	49
7.16	Download and Maintenance	49
7.17	Bug Report and Feature Requests	50
III	RESULTS	52
8	IDENTIFICATION OF FBXO30 - A NEW MEMBER OF THE INSULIN SIGNALLING PATHWAY	53
8.1	Phosphorylation signature in liver of db/db animals	53
8.2	Insulin-Dependent Phosphorylation of FBXO30 at Serine 383 in-vivo	56
8.3	FBXO30 is phosphorylated by and interacts with ERK1/2	58
9	REGULATION OF FBXO30 IN RESPONSE TO REFEEDING	63
9.1	Regulation in response to refeeding in db/db mice	67
10	FBXO30 SUBSTRATE SCREENING AND INTERACTION PARTNER IDENTIFICATION	69
10.1	Unbiased GlyGly enrichment	71
10.2	Immunoprecipitation	74
10.3	Proximity Labelling	76
11	GENERATION AND CHARACTERIZATION OF FBXO30 ^{-/-} MOUSE	81
11.1	High fat diet administration	81
	Body weight curve	82
	Glucose tolerance test	82
	Insulin tolerance test	83
	μ-CT Scans	84

12	DEVELOPMENT OF AN VISUALIZATION AND ANALYSIS TOOL -	
	INSTANTCLUE	85
12.1	Data organization and plotting	85
12.2	Computational activities and data filtering	86
12.3	Statistical Toolbox for multivariate data analysis	88
12.3.1	(Un-)Supervised Learning for data classification	88
12.3.2	Time series analysis	89
12.3.3	Curve fitting and correlation analysis	89
12.4	The Main Figure Template	90
IV	DISCUSSION	92
13	FBXO30	93
	Regulation of FBXO30 by S383 phosphorylation and	
	potential substrates	93
13.1	Regulation of Fbxo30 in other datasets	94
13.2	Fbxo30 phosphorylation	96
13.3	Comparison to other insulin/IGF-1 dependent E3 Ligases shows	
	a distinct function of FBXO30	97
13.4	Global GylGly remnant screen identifies novel Substrates of	
	FBXO30	98
13.4.1	ERK inhibition might attenuate glucose influx via FBXO30	99
	Known substrates of FBXO30	100
	FBXO30 substrate prediction	100
13.5	Role of Fbxo30 in BMP signalling and atrophy in muscle	101
13.6	Physiological Role of Fbxo30	102
13.6.1	Tissue specific functions of FBXO30?	102
13.7	Future Perspective	102
13.7.1	Substrate validation of FBXO30	102
13.7.2	Hyperinsulinemic-euglycemic clamp	103
13.7.3	Generating S383A and S383D mice.	103
14	INSTANT CLUE	104
14.0.1	Comparison with other tools.	104
14.1	Future perspective	107
V	APPENDIX	108
	BIBLIOGRAPHY	109
15	SUPPLEMENTARY INFORMATION	135
15.1	Supplementary Figures	135
16	ATTACHED DATA	143
VI	ERKLÄRUNG ZUR DISSERTATION	144
17	ERKLÄRUNG ZUR DISSERTATION	145